Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 16.03% |
| TRI TECH HOL | TRIT | 10.00% |
| A M R CP | AAMRQ | 8.14% |
| JAZZ PHARMAC | JAZZ | 6.00% |
| SANTARUS INC | SNTS | 5.38% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
HeartWare International Inc. ( HTWR - Snapshot Report ) , a global provider of miniaturized ventricular assist devices (VAD) for diagnosis of advanced heart failure, recently announced that it has closed its acquisition of WorldHeart Corporation (WHRT) after obtaining the approval of the latter's stockholders.
The acquisition is expected to enhance HeartWare’s available product portfolio by including WorldHeart’s advanced technology. Management at HeartWare asserts that the acquisition underlines the company’s near-term focus of global leadership in the ventricular assist device (VAD) market.
WorldHeart is also a global provider of mechanical circulatory support systems. It is currently developing an advanced continuous flow pump, the MiFlow VAD. The company’s technical know-how and skill set is expected to boost HeartWare’s research efforts. The merger will not only complement HeartWare’s existing product line, but also bolster its intellectual property portfolio.
Per the agreement, HeartWare acquired and merged the outstanding voting securities of WorldHeart for $8 million of its common stock. The amount is based on the terms and conditions of the acquisition. As calculated, each share of WorldHeart common stock has been altered into the right to procure 0.003 shares of HeartWare common stock.
Following the issuance of around 83,000 new shares of HeartWare common stock to WorldHeart stockholders, HeartWare outstanding common stock will increase to roughly 14,275,000 shares.
Headquartered in Framingham, Massachusetts, HeartWare is an innovator and producer of miniaturized implantable heart pumps. The company faces a tough competitive landscape with Thoratec Corp ( THOR - Analyst Report ) .
The HeartWare Ventricular Assist System is currently under FDA review since the company submitted its Premarket Approval (PMA) application in December 2010. Once approved, HeartWare is expected to close the technological gap and end Thoratec’s dominance for the bridge-to-transplant (BTT) indication.
HeartWare currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Analyst Report on THOR
Read the full Snapshot Report on HTWR